Zdrowie i gospodarka · 05/07/2013

FDA Extends Comment Period for Lung Cancer Patient-Focused Drug Development

The US Food and Drug Administration (FDA) is extending the public comment period for its lung cancer patient-focused drug development initiative, allowing interested individuals more time to submit their thoughts on the topic, which was initially set to close on July 29, 2013.